The discovery of melatonin receptors on prostate cancer cells, especially MT1, significantly improved understanding of the molecular mechanisms underlying melatonin’s antitumor activity in advanced prostate cancer. This evidence concerns the gene MTNR1A and Familial prostate cancer.